Singapore O&G Ltd: Completing the life cycle October 5, 2017 2796

PSR Recommendation: BUY Status: Maintained
Target Price: SGD0.65

What is the news?

Service agreement with KL Fertility & Gynaecology Centre Sdn. Bhd. (“KL Fertility Centre”) on 3 Oct-17

  • The Group has entered into a commercial collaboration with KL Fertility Centre, a wholly owned subsidiary of Monash IVF Group Ltd based in Australia.
  • This collaboration will enable SOG to offer new and existing patients with Assisted Reproductive Technology (“ART”) services such as In-Vitro Fertilisation (“IVF”) and Intracytoplasmic Sperm Injection (“ICSI”) Procedures.
  • The collaboration is for an initial term of 36 months and is limited to the Singapore market only.

How does it work?

  • An IVF treatment cycle can be broken down into two segments (See Figure 1):
  1. SOG to conduct initial investigations, consultations and stimulations.
  2. SOG will refer patients to KL Fertility Centre for ART services.

Nonetheless, specialists from both SOG and KL Fertility Centre would work hand in hand throughout the entire cycle.

  • Target to commence in early-2018.
  • While all six O&G specialists are certified to provide such services, SOG plans to have 2-3 designated specialists to carry out such activities as the patients undergoing medication will require more time and attention. Patient undergoing stimulation injections are required to visit the clinics in every 2-4 days to monitor follicles development.
  • Appeals to cost-conscious patients and Singaporeans who had exhausted their government subsidy for ART. Savings could be up to 25%, while receiving quality private healthcare services.
  • No fee sharing. Patients will pay for ovarian stimulation fees to SOG and IVF services costs to KL Fertility Centre separately.

 What do we think?

  • This completes SOG as a holistic care for women’s wellness with multidisciplinary team approach, and without incurring additional CAPEX.
  • The structural change in Singapore underpins demand for fertility services. About 15% of the couples in Singapore face infertility issues. With the median age at first marriage and first birth rising, we believe that there is an increasing number of couples who need medical help in conceiving.
  • The strategic partnership enables SOG to capture part of the value chain – on consultancy, monitoring, and drug prescriptions. Previously, SOG has been referring its patients to external fertility centre.
  • It could also unfold multiple opportunities for future revenue growth. If pregnancy occurs, the patient could eventually return to SOG for obstetrical, aesthetic and paediatric services.
  • We do not expect the new initiative to have a significant impact on FY18e margin. Management shared that the pricing structure for drugs, diagnostic tests and scans, as well as consultation will be similar to its current business model. Obstetrics services will remain as the most profitable business. Hence, we expect EBIT margin for ovarian stimulation to be in the range of 30-35%. A higher than expected demand for fertility services would be an upside catalyst.

Maintained Buy rating with TP of S$0.65 based on FY18e EPS of 2.24 Cents pegged to a forward PER of 29x.

 

Figure 1: One full IVF cycle

1

Source: PSR

What are IVF and ICSI?

  • In-Vitro Fertilisation (“IVF”) involves putting the eggs and sperms together and fertilisation occurs by natural selection.
  • While Intracytoplasmic Sperm Injection (“ICSI”) involves injecting a single sperm into each egg to allow fertilisation to occur.
  • After fertilisation, the embryos are allowed to grow for a short period of time before being placed into the uterus.
  • A successful pregnancy can be confirmed about two weeks later.
  • The success rate is likely to fall with age.

Figure 2: ICSI Procedures

2

Source: Singhealth website

How does SOG differ?

Price competitiveness

  • Due to the complexities of the process, expensive equipment, and scarce production of the hormones (there are only a handful of companies worldwide), such treatment can be very costly.
  • Range of cost for a full IVF cycle in Singapore = S$10,000 to S$15,000 (Public); S$12,000 to S$20,000 (Private)
  • Range of cost for a full IVF cycle in Malaysia = RM15,000 to RM25,000
  • Medisave can be used to co-pay SOG’s bill; While the IVF cost (i.e. payment to KL Fertility Centre) will follow the rate in Malaysia.

Based on a report on IVF, published by MOH in 2004:

In 2002, 67% of the IVF cycles was done in public IVF centres, and 33% in private.

There were more private IVF centres set up since 2002, e.g.  Raffles Medical Group and Sincere Healthcare Group. We believe that the mix should remain around 70:30.

Singapore government has instituted measures to relieve the financial burden and to push for higher fertility rate

  1. Medisave for Assisted Conception Procedures
  • Lifetime withdrawal limit for each patient of $15,000 for out-of-pocket costs for Assisted Conception Procedures

Figure 3:

3

Source: HeyBaby.sg

 

  1. Government Co-Funding Scheme for Assisted Reproduction Technology (ART) Treatment
  • Up to 75% in co-funding from the Government for ART treatment cycles, for a maximum of 3 fresh and 3 frozen ART cycles
  • Only available at AR centres in Singapore public hospitals, namely at National University Hospital (NUH), Singapore General Hospital (SGH), and KK Women’s and Children’s Hospital (KKH)

Figure 4:

4

Source: HeyBaby.sg

MOH has co-funded 3,512 assisted reproduction cycles in 2015, up from 3,173 cycles in 2014 and 2,749 cycles in 2013.

The IVF market in Singapore is estimated to worth over S$75mn.

Assuming:

  • The 3,512 cycles formed the 70% total cycles done in 2015, based on the 70:30 public-private mi
  • The average cost is S$15,000 per cycle

Important Information

This report is prepared and/or distributed by Phillip Securities Research Pte Ltd ("Phillip Securities Research"), which is a holder of a financial adviser’s licence under the Financial Advisers Act, Chapter 110 in Singapore.

By receiving or reading this report, you agree to be bound by the terms and limitations set out below. Any failure to comply with these terms and limitations may constitute a violation of law. This report has been provided to you for personal use only and shall not be reproduced, distributed or published by you in whole or in part, for any purpose. If you have received this report by mistake, please delete or destroy it, and notify the sender immediately.

The information and any analysis, forecasts, projections, expectations and opinions (collectively, the “Research”) contained in this report has been obtained from public sources which Phillip Securities Research believes to be reliable. However, Phillip Securities Research does not make any representation or warranty, express or implied that such information or Research is accurate, complete or appropriate or should be relied upon as such. Any such information or Research contained in this report is subject to change, and Phillip Securities Research shall not have any responsibility to maintain or update the information or Research made available or to supply any corrections, updates or releases in connection therewith.

Any opinions, forecasts, assumptions, estimates, valuations and prices contained in this report are as of the date indicated and are subject to change at any time without prior notice. Past performance of any product referred to in this report is not indicative of future results.

This report does not constitute, and should not be used as a substitute for, tax, legal or investment advice. This report should not be relied upon exclusively or as authoritative, without further being subject to the recipient’s own independent verification and exercise of judgment. The fact that this report has been made available constitutes neither a recommendation to enter into a particular transaction, nor a representation that any product described in this report is suitable or appropriate for the recipient. Recipients should be aware that many of the products, which may be described in this report involve significant risks and may not be suitable for all investors, and that any decision to enter into transactions involving such products should not be made, unless all such risks are understood and an independent determination has been made that such transactions would be appropriate. Any discussion of the risks contained herein with respect to any product should not be considered to be a disclosure of all risks or a complete discussion of such risks.

Nothing in this report shall be construed to be an offer or solicitation for the purchase or sale of any product. Any decision to purchase any product mentioned in this report should take into account existing public information, including any registered prospectus in respect of such product.

Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may provide an array of financial services to a large number of corporations in Singapore and worldwide, including but not limited to commercial / investment banking activities (including sponsorship, financial advisory or underwriting activities), brokerage or securities trading activities. Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may have participated in or invested in transactions with the issuer(s) of the securities mentioned in this report, and may have performed services for or solicited business from such issuers. Additionally, Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may have provided advice or investment services to such companies and investments or related investments, as may be mentioned in this report.

Phillip Securities Research or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report may, from time to time maintain a long or short position in securities referred to herein, or in related futures or options, purchase or sell, make a market in, or engage in any other transaction involving such securities, and earn brokerage or other compensation in respect of the foregoing. Investments will be denominated in various currencies including US dollars and Euro and thus will be subject to any fluctuation in exchange rates between US dollars and Euro or foreign currencies and the currency of your own jurisdiction. Such fluctuations may have an adverse effect on the value, price or income return of the investment.

To the extent permitted by law, Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may at any time engage in any of the above activities as set out above or otherwise hold an interest, whether material or not, in respect of companies and investments or related investments, which may be mentioned in this report. Accordingly, information may be available to Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, which is not reflected in this report, and Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may, to the extent permitted by law, have acted upon or used the information prior to or immediately following its publication. Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited its officers, directors, employees or persons involved in the issuance of this report, may have issued other material that is inconsistent with, or reach different conclusions from, the contents of this report.

The information, tools and material presented herein are not directed, intended for distribution to or use by, any person or entity in any jurisdiction or country where such distribution, publication, availability or use would be contrary to the applicable law or regulation or which would subject Phillip Securities Research to any registration or licensing or other requirement, or penalty for contravention of such requirements within such jurisdiction.

This report is intended for general circulation only and does not take into account the specific investment objectives, financial situation or particular needs of any particular person. The products mentioned in this report may not be suitable for all investors and a person receiving or reading this report should seek advice from a professional and financial adviser regarding the legal, business, financial, tax and other aspects including the suitability of such products, taking into account the specific investment objectives, financial situation or particular needs of that person, before making a commitment to invest in any of such products.

This report is not intended for distribution, publication to or use by any person in any jurisdiction outside of Singapore or any other jurisdiction as Phillip Securities Research may determine in its absolute discretion.

IMPORTANT DISCLOSURES FOR INCLUDED RESEARCH ANALYSES OR REPORTS OF FOREIGN RESEARCH HOUSE

Where the report contains research analyses or reports from a foreign research house, please note:

  1. recipients of the analyses or reports are to contact Phillip Securities Research (and not the relevant foreign research house) in Singapore at 250 North Bridge Road, #06-00 Raffles City Tower, Singapore 179101, telephone number +65 6533 6001, in respect of any matters arising from, or in connection with, the analyses or reports; and
  2. to the extent that the analyses or reports are delivered to and intended to be received by any person in Singapore who is not an accredited investor, expert investor or institutional investor, Phillip Securities Research accepts legal responsibility for the contents of the analyses or reports.
Subscribe
Notify of
guest
0 Comments
Inline Feedbacks
View all comments

About the author

Profile photo of Soh Lin Sin

Soh Lin Sin
Investment Analyst
Phillip Securities Research Pte Ltd

Lin Sin has been an investment analyst in Phillip Securities Research since June 2014, where she started as an economist, focusing on China and ASEAN macroeconomics. Currently, she covers primarily the Consumers and Healthcare sectors in Singapore equities market.

She graduated with a Bachelor of Science in Mathematics and Economics from NTU.

Get access to all the latest market news, reports, technical analysis
by signing up for a free account today!